GR20100100508A - Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου - Google Patents
Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμουInfo
- Publication number
- GR20100100508A GR20100100508A GR20100100508A GR20100100508A GR20100100508A GR 20100100508 A GR20100100508 A GR 20100100508A GR 20100100508 A GR20100100508 A GR 20100100508A GR 20100100508 A GR20100100508 A GR 20100100508A GR 20100100508 A GR20100100508 A GR 20100100508A
- Authority
- GR
- Greece
- Prior art keywords
- drinkable
- hypothyroidism
- treatment
- pharmaceutical solutions
- solutions
- Prior art date
Links
- 239000003186 pharmaceutical solution Substances 0.000 title abstract 2
- 208000003532 hypothyroidism Diseases 0.000 title 1
- 230000002989 hypothyroidism Effects 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 abstract 1
- 229960003918 levothyroxine sodium Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Σταθερά πόσιμα φαρμακευτικά διαλύματα τα οποία εύκολα μπορούν να μορφοποιηθούν σε πόσιμες σταγόνες και τα οποία περιλαμβάνουν νατριούχα λεβοθυροξίνη ως δραστικό συστατικό και έναν συνδυασμό αιθανόλης, προπυλενογλυκόλης και νερού. Τα πόσιμα διαλύματα της παρούσας εφεύρεσης παραμένουν φυσικοχημικώς σταθερά όταν αποθηκεύονται, για τουλάχιστον τρεις μήνες σε θερμοκρασία 25 βαθμοί Κελσίου και σχετικήυγρασία 60 τοις εκατό.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20100100508A GR20100100508A (el) | 2010-09-10 | 2010-09-10 | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20100100508A GR20100100508A (el) | 2010-09-10 | 2010-09-10 | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR20100100508A true GR20100100508A (el) | 2012-04-30 |
Family
ID=45954096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20100100508A GR20100100508A (el) | 2010-09-10 | 2010-09-10 | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR20100100508A (el) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2692340A1 (en) * | 2012-08-03 | 2014-02-05 | Verisfield (UK) Ltd. | Stable pharmaceutical system (kit) for the preparation of oral solution of levothyroxine or pharmaceutically acceptable salt thereof |
| WO2025056929A1 (en) | 2023-09-15 | 2025-03-20 | Ioulia Tseti | Sealed single-dose container of levothyroxine aqueous solution suitable for oral administration |
-
2010
- 2010-09-10 GR GR20100100508A patent/GR20100100508A/el not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2692340A1 (en) * | 2012-08-03 | 2014-02-05 | Verisfield (UK) Ltd. | Stable pharmaceutical system (kit) for the preparation of oral solution of levothyroxine or pharmaceutically acceptable salt thereof |
| WO2025056929A1 (en) | 2023-09-15 | 2025-03-20 | Ioulia Tseti | Sealed single-dose container of levothyroxine aqueous solution suitable for oral administration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01233A (el) | ||
| PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
| UA105229C2 (uk) | Фармацевтичний склад | |
| WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| EP3626253A3 (en) | Stable formulations of linaclotide | |
| SG171542A1 (en) | Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin | |
| GEP20146015B (en) | Novel acetylsalicylic acid salts | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| WO2008053297A3 (en) | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| BR112014002940A2 (pt) | uso e composição agroquímica de dibutilamidas de ácido carboxílico | |
| UA100394C2 (en) | Lipoic acid pellet composition | |
| WO2012075015A3 (en) | Oral metronidazole pharmaceutical compositions | |
| EA201201239A1 (ru) | Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| MX2009010483A (es) | 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas. | |
| UA103290C2 (ru) | Фармацевтическая композиция ибупрофена для инъекции | |
| GR20100100508A (el) | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου | |
| EA201290485A1 (ru) | Производные бензамида | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| MX2009005329A (es) | Composiciones farmaceuticas anticonvulsivas. | |
| EA201270547A1 (ru) | Фармацевтическая композиция | |
| ZA200805598B (en) | Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid | |
| CL2008002725A1 (es) | Compuestos derivados de sales de acido 1,2,5-oxadiazol de perindropil o perindoprilato como inhibidores de la enzima convertidora de angiotensina; procedimiento de preparacion; composiciones farmaceuticas de dichos compuestos; su uso para el tratamiento de patologias cardiovasculares, inflamacion y estres oxidativo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |
Effective date: 20140403 |